Immunome (IMNM) Return on Capital Employed: 2023-2025
Historic Return on Capital Employed for Immunome (IMNM) over the last 2 years, with Sep 2025 value amounting to -0.88%.
- Immunome's Return on Capital Employed rose 46.00% to -0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.88%, marking a year-over-year increase of 46.00%. This contributed to the annual value of -2.18% for FY2024, which is N/A change from last year.
- Latest data reveals that Immunome reported Return on Capital Employed of -0.88% as of Q3 2025, which was down 16.11% from -0.76% recorded in Q2 2025.
- Over the past 5 years, Immunome's Return on Capital Employed peaked at -0.76% during Q2 2025, and registered a low of -1.57% during Q4 2024.
- Over the past 3 years, Immunome's median Return on Capital Employed value was -1.06% (recorded in 2024), while the average stood at -1.08%.
- As far as peak fluctuations go, Immunome's Return on Capital Employed tumbled by 47bps in 2024, and later soared by 46bps in 2025.
- Over the past 3 years, Immunome's Return on Capital Employed (Quarterly) stood at -1.11% in 2023, then crashed by 47bps to -1.57% in 2024, then spiked by 46bps to -0.88% in 2025.
- Its last three reported values are -0.88% in Q3 2025, -0.76% for Q2 2025, and -0.84% during Q1 2025.